Amarin (NASDAQ:AMRN) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen lowered shares of Amarin (NASDAQ:AMRN) from a buy rating to a hold rating in a research report released on Saturday morning.

Several other brokerages have also recently issued reports on AMRN. Zacks Research upgraded shares of Amarin from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Amarin in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Amarin has an average rating of “Moderate Buy”.

Amarin Trading Down 0.4%

NASDAQ AMRN opened at $13.55 on Friday. The stock has a market cap of $284.14 million, a price-to-earnings ratio of -20.85 and a beta of 0.80. Amarin has a 12 month low of $12.96 and a 12 month high of $20.90. The company’s 50 day moving average is $14.90 and its two-hundred day moving average is $14.88.

Institutional Trading of Amarin

Several institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Amarin by 197.4% in the second quarter. GAMMA Investing LLC now owns 1,576 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 1,046 shares during the period. Two Sigma Investments LP boosted its holdings in Amarin by 1.8% during the third quarter. Two Sigma Investments LP now owns 60,071 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 1,047 shares in the last quarter. Sei Investments Co. grew its position in Amarin by 4.7% during the third quarter. Sei Investments Co. now owns 29,212 shares of the biopharmaceutical company’s stock worth $478,000 after buying an additional 1,299 shares during the period. Banque Cantonale Vaudoise purchased a new position in Amarin in the third quarter valued at about $32,000. Finally, Ameriprise Financial Inc. increased its holdings in Amarin by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,008 shares in the last quarter. Institutional investors and hedge funds own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.